---
title: "China NT Pharma Calls 2026 AGM, Seeks Renewal of Share Issuance Mandate"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284750140.md"
description: "China NT Pharma Group Co., Ltd. has scheduled its annual general meeting for June 4, 2026, in Hong Kong. The agenda includes reviewing financial statements, re-electing directors, and appointing auditors. Shareholders will also vote on granting a mandate to issue up to 20% of existing share capital, enhancing the company's financial flexibility for capital raising and corporate transactions. The company operates in the healthcare sector and is listed on the Hong Kong Stock Exchange under stock code 1011, with a current market cap of HK$635.8M."
datetime: "2026-04-30T10:47:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284750140.md)
  - [en](https://longbridge.com/en/news/284750140.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284750140.md)
---

# China NT Pharma Calls 2026 AGM, Seeks Renewal of Share Issuance Mandate

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

China NT Pharma Group Co., Ltd. ( (HK:1011) ) just unveiled an announcement.

China NT Pharma Group Company Limited has convened its annual general meeting for 4 June 2026 in Hong Kong to review and adopt the audited consolidated financial statements and directors’ and auditors’ reports for the financial year ended 31 December 2025. Shareholders will also vote on the re-election of three retiring directors, the authorization of directors’ remuneration, and the re-appointment of Moore CPA Limited as the company’s auditors.

The meeting will further seek shareholder approval to grant the board a general mandate to issue up to 20% of the company’s existing share capital, including related options, warrants, and convertible securities, subject to Hong Kong listing rules. This proposed issuance mandate, which is additional to existing authorisations, would enhance the company’s financial and strategic flexibility by enabling potential capital raising, corporate transactions, or incentive schemes without requiring separate approvals for each action.

**More about China NT Pharma Group Co., Ltd.**

China NT Pharma Group Company Limited is a Hong Kong–listed company incorporated in the Cayman Islands and traded under stock code 1011. It operates within the healthcare and pharmaceutical sector, with its governance and capital management subject to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

**Average Trading Volume:** 251,362

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$635.8M

### Related Stocks

- [01011.HK](https://longbridge.com/en/quote/01011.HK.md)

## Related News & Research

- [China NT Pharma Says Director’s Judicial Records Tied to Settled Subsidiary Loan, No Material Impact Seen](https://longbridge.com/en/news/286577625.md)
- [A city at the center of an AI data center frenzy just voted to ban them](https://longbridge.com/en/news/287107998.md)
- [ELFI offers new private student loan alternative for medical and healthcare students facing federal loan changes](https://longbridge.com/en/news/286929682.md)
- [The Trading Awards: Voting is open until 19 May](https://longbridge.com/en/news/286793607.md)
- [A Look At SCHOTT Pharma KGaA (XTRA:1SXP) Valuation After Weaker Profitability In Latest Earnings](https://longbridge.com/en/news/287181929.md)